Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
出版年份 2018 全文链接
标题
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
作者
关键词
-
出版物
NATURE MEDICINE
Volume 24, Issue 12, Pages 1877-1886
出版商
Springer Nature
发表日期
2018-10-26
DOI
10.1038/s41591-018-0217-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Translation initiation factors and their relevance in cancer
- (2018) Columba de la Parra et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Eukaryotic initiation factor 4F — sidestepping resistance mechanisms arising from expression heterogeneity
- (2018) Jennifer Chu et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
- (2017) Riccardo Mezzadra et al. NATURE
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma
- (2017) Coralie Dorard et al. Nature Communications
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Deubiquitination and Stabilization of PD-L1 by CSN5
- (2016) Seung-Oe Lim et al. CANCER CELL
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines
- (2016) Hélène Malka-Mahieu et al. CELL CYCLE
- Developing anti-neoplastic biotherapeutics against eIF4F
- (2016) Jutta Steinberger et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
- (2016) Hélène Malka-Mahieu et al. CLINICAL CANCER RESEARCH
- Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy
- (2016) James L. Reading et al. IMMUNITY
- What does PD-L1 positive or negative mean?
- (2016) Antoni Ribas et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer
- (2016) Jennifer Chu et al. TRENDS IN CELL BIOLOGY
- CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A
- (2016) Jennifer Chu et al. Cell Reports
- Targeting the eIF4A RNA helicase as an anti-neoplastic approach
- (2015) Jennifer Chu et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
- (2015) J. Pelletier et al. CANCER RESEARCH
- Targeting the translation machinery in cancer
- (2015) Mamatha Bhat et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis
- (2015) Mélanie Tichet et al. Nature Communications
- The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease
- (2015) John T. Patton et al. Oncotarget
- RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
- (2014) Andrew L. Wolfe et al. NATURE
- eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
- (2014) Lise Boussemart et al. NATURE
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
- (2014) Z. A. Cooper et al. Cancer Immunology Research
- Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A–RNA Complex
- (2013) Heather Sadlish et al. ACS Chemical Biology
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Targeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes Tumorigenesis
- (2012) Chen-Ju Lin et al. Cell Reports
- Formation of the eIF4F Translation-Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors
- (2011) P. Zindy et al. CANCER RESEARCH
- Efficient Suppression of Gene Expression by Targeting 5′-UTR-Based RNA Quadruplexes with Bisquinolinium Compounds
- (2011) Kangkan Halder et al. CHEMBIOCHEM
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
- (2009) Nathalie Dhomen et al. CANCER CELL
- In Vitro and In Vivo Anti-Melanoma Effects of Ciglitazone
- (2009) Thomas Botton et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
- (2009) Regina Cencic et al. PLoS One
- Translational control of the innate immune response through IRF-7
- (2008) Rodney Colina et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search